Biogen Inc. Common Stock (BIIB)
Stock · NASDAQ · Health Care
$232.65as of 10/16/2026
Price chart
Active signals
BIIB Signal Track Record
How signals performed across all stocks →What BIIB's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 34 | -1.1% | 41% | September 18, 2026 |
| Bollinger Band Breakout | 23 | -0.3% | 48% | September 23, 2026 |
| Bollinger Band Breakdown | 21 | -4.9% | 24% | April 2, 2026 |
| 200-Day Moving Average TouchActive now | 8 | -4.3% | 38% | September 25, 2025 |
| Any 20-session window (baseline) | -0.5% | 47% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About BIIB
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etan…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 7,500
- Website
- www.biogen.com/
Fundamentals
- 1-day range
- $232.48$236.35
- Market cap
- $30.48B
- P/E (trailing)
- 42.27
- P/E (forward)
- 14.22
- EPS (trailing)
- $5.65
- Dividend yield
- —
- Beta
- 0.10
- Avg. volume
- 993.1K
How Biogen Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 6, 2026 · via SEC EDGAR / Finnhub
Forecasts
32 analyst ratings
Biogen Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- BIIBBiogen Inc. Common Stock$232.65▼ 1.15%Market cap $30.48BP/E 42.27$138$238.24
- BNTXBioNTech SE American Depositary Share$87.71▼ 2.76%Market cap $22.91BP/E —$79.52$124
- MRNAModerna Inc. Common Stock$218.01▼ 7.82%Market cap $21.50BP/E —$22.28$227.46
- RVMDRevolution Medicines Inc. Common Stock$177.96▼ 5.97%Market cap $42.05BP/E —$47.45$224.31
- NBIXNeurocrine Biosciences Inc. Common Stock$135.71▼ 0.91%Market cap $16.25BP/E 19.57$122.14$186.12
- EXELExelixis Inc. Common Stock$62.23▼ 0.95%Market cap $13.12BP/E 17.49$33.76$61.66
- HALOHalozyme Therapeutics Inc. Common Stock$121.84▲ 0.27%Market cap $10.17BP/E 32.51$61.23$119.21
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| BIIB Biogen Inc. Common Stock | $30.48B | 42.27 | $232.65 | ▼ 1.15% | $138$238.24 |
| BNTX BioNTech SE American Depositary Share | $22.91B | — | $87.71 | ▼ 2.76% | $79.52$124 |
| MRNA Moderna Inc. Common Stock | $21.50B | — | $218.01 | ▼ 7.82% | $22.28$227.46 |
| RVMD Revolution Medicines Inc. Common Stock | $42.05B | — | $177.96 | ▼ 5.97% | $47.45$224.31 |
| NBIX Neurocrine Biosciences Inc. Common Stock | $16.25B | 19.57 | $135.71 | ▼ 0.91% | $122.14$186.12 |
| EXEL Exelixis Inc. Common Stock | $13.12B | 17.49 | $62.23 | ▼ 0.95% | $33.76$61.66 |
| HALO Halozyme Therapeutics Inc. Common Stock | $10.17B | 32.51 | $121.84 | ▲ 0.27% | $61.23$119.21 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- UBS Maintains Buy on Biogen, Raises Price Target to $270Benzinga · 10/9/2026
- RBC Capital Maintains Outperform on Biogen, Lowers Price Target to $256Benzinga · 10/8/2026
- Stock Picks From Seeking Alpha's September 2026 New AnalystsSeekingAlpha · 10/7/2026
- Biogen expected to slightly beat third-quarter earnings as lupus trial data loom, Jefferies saysYahoo · 10/6/2026
- Will Biogen (BIIB) Beat Estimates Again in Its Next Earnings Report?Yahoo · 10/6/2026
- 4 Health Care Stocks With Whale Alerts In Today’s SessionBenzinga · 10/5/2026
- Design Therapeutics: 'Hold' DT-216P2 Registrational FA Plans Q4 2026 And 12-Week Results Q1 2027SeekingAlpha · 10/4/2026
- Biogen’s Litifilimab Demonstrates Rapid and Durable Efficacy in New 52-Week Phase 2 Data from Ongoing Phase 2/3 AMETHYST Study, Reinforcing Its Potential as a First-in-Class Therapy for Cutaneous Lupus ErythematosusYahoo · 10/2/2026
Insider Activity
Insider Actions →- Sean Godbout · October 2, 2026 · Option Exercise27
- Sean Godbout · October 2, 2026 · Tax Withholding8 @ $219.88
- Sean Godbout · October 1, 2026 · Grant985
- Parini Michael · September 1, 2026 · Grant7.4K
- Lloyd Minor · August 4, 2026 · Sale593 @ $200.96
- Lloyd Minor · August 3, 2026 · Sale593 @ $203.34
- Lloyd Minor · June 9, 2026 · Grant1.5K
- Menelas N. Pangalos · June 9, 2026 · Option Exercise2.4K
- Menelas N. Pangalos · June 9, 2026 · Grant1.5K
- Susan Langer · June 9, 2026 · Grant1.5K
- Monish D. Patolawala · June 9, 2026 · Grant1.5K
- Jesus B. Mantas · June 9, 2026 · Grant1.5K
- Maria C. Freire · June 9, 2026 · Grant2.0K
- Eric K. Rowinsky · June 9, 2026 · Grant1.5K
- William A. Hawkins · June 9, 2026 · Grant1.5K
Institutional Ownership
March 31, 2026
- Total shares held
- 127.03M
- Total value held
- $22.35B
- Institutional holders
- 986
- Unknown15.97M
- Unknown14.76M
- Unknown12.81M
- Unknown9.54M
- Unknown7.17M
- Unknown4.34M
- Unknown2.96M
- Unknown2.17M
- Unknown1.92M
- Unknown1.75M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Biogen sees kidney therapy progress and rating upgrade
Biogen is receiving attention after a kidney transplant milestone was reported, highlighting its involvement in kidney disease research. The company’s partner Estuary Therapeutics raised $93 million to advance a gene‑therapy for kidney disease, adding to the pipeline focus. Analysts have upgraded Biogen’s outlook, noting growth potential beyond its Alzheimer’s products. An earnings preview also points to upcoming results that could shape market views.
Biogen sees kidney therapy progress and rating upgrade. Biogen is receiving attention after a kidney transplant milestone was reported, highlighting its involvement in kidney disease research. The company’s partner Estuary Therapeutics raised $93 million to advance a gene‑therapy for kidney disease, adding to the pipeline focus. Analysts have upgraded Biogen’s outlook, noting growth potential beyond its Alzheimer’s products. An earnings preview also points to upcoming results that could shape market views.